RLMD – relmada therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: TRAVERSA SERGIO
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Ence Chuck
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Shenouda Maged
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: GLASSPOOL JOHN
Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Fedeli Fabiana
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.